BIOX
Overvalued by 327.3% based on the discounted cash flow analysis.
Market cap | $287.84 Million |
---|---|
Enterprise Value | $553.04 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.05 |
Beta | 0.6 |
Outstanding Shares | 62,822,158 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 112.23 |
---|---|
PEG | 567.3 |
Price to Sales | 0.67 |
Price to Book Ratio | 0.94 |
Enterprise Value to Revenue | 1.25 |
Enterprise Value to EBIT | 12.89 |
Enterprise Value to Net Income | 220 |
Total Debt to Enterprise | 0.53 |
Debt to Equity | 0.95 |
No data
No data